Compare Deere & Company (DE) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Quest Diagnostics Inc — how do they compare? Deere & Company trades at $652.58 (market cap $177.11B), while Quest Diagnostics Inc trades at $230.72 (market cap $25.06B). The key difference: Deere & Company is far larger — about 7.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.52%). Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Quest Diagnostics Inc for 56 Days on average.
| DE | DGX | |
|---|---|---|
Market Cap | $177.11B | $25.06B |
Volume | 1,206,308 | 927,361 |
Sector | Industrials | Health |
52-Week High | $709.48 | $247.45 |
52-Week Low | $439.11 | $173.49 |
Typical Hold Time | 75 Days | 56 Days |
Enterprise Value | $231.01B | $30.82B |
Dividend Yield | 0.99% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $652.58, down 4.42% today, showing bearish technical signals with support at $643 and resistance at $658. The company maintains strong profitability with a 10.39% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Deere's AI initiatives and institutional buying interest, though revenue has declined from 2023 peaks.
Deere presents a mixed outlook with solid fundamentals and analyst support (43.48% buy rating, $731.20 target) but faces agricultural cycle headwinds and competitive pressures. The stock offers potential upside from AI-driven farming solutions but risks include cyclical demand volatility and high debt levels at 60.31% of assets.
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
